Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07147166 · ClinicalTrials.gov registry record · NA

Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

A NA study of Mastectomy and Gender Dysphoria, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
78
Enrollment target
1
Study location

NCT07147166 is a NA study of Mastectomy and Gender Dysphoria that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 78 participants, below the 123-participant average among 8 other Mastectomy trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07147166, a NA study of Mastectomy and Gender Dysphoria, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision mastectomies at a single-institution, single-surgeon site (Esther A. Kim, MD). Patients will serve as a self-control (one side of the chest receives intervention, the other serves as a control). Primary endpoints include scar appearance and quality. Secondary endpoints include patient perception of the scar using the Patient and Observer Scar Assessment Scale (POSAS). Participants will be taught how to apply Brijjit® at home if any units fall off before 6 weeks postop.

Interventions

  • DEVICE Brijjit® BP100-6 and BP-75
  • OTHER Control: Standard of care and normal wound dressing

Study Locations (1)

California

  • UCSF Department of Plastic & Reconstructive Surgery - San Francisco

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2025-02-03
Est. Completion 2027-06-01
Phase NA

What the Registry Record Tells You About NCT07147166

The ClinicalTrials.gov registry entry for NCT07147166 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 8 other Mastectomy trials with a reported enrollment target (37% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Mastectomy appearing as the primary indexed condition, and to 2 interventions - of which Brijjit® BP100-6 and BP-75 is the first listed.

NCT07147166 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT07147166 about?

NCT07147166 is a clinical study titled "Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy". The goal of this randomized, prospective, interventional clinical trial is to evaluate the use of Brijjit® in reducing the incidence of hypertrophic scarring in individuals undergoing gender-affirming bilateral double incision mastectomies at a single-institution, single-surgeon site (Esther A. Kim,...

What is the current status of trial NCT07147166?

This trial is currently recruiting. It is a NA study. The enrollment target is 78 participants. The study started on 2025-02-03. Estimated completion is 2027-06-01.

What conditions does trial NCT07147166 study?

This clinical trial studies the following conditions: Mastectomy, Gender Dysphoria, Hypertrophic Scar.

What interventions are being tested in trial NCT07147166?

The interventions under investigation include: Brijjit® BP100-6 and BP-75 (DEVICE), Control: Standard of care and normal wound dressing (OTHER).

Who is sponsoring clinical trial NCT07147166?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07147166 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mastectomy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.